Mariposa Therapeutics Limited

Mariposa Therapeutics is a seed-stage biotech company headquartered in Cardiff, Wales, incorporated in 2019. It develops MP5219, a first-in-class disease-modifying treatment for Epidermolysis Bullosa Simplex (EBS), a rare genetic skin disease, using synthetic analogues of ajoene to activate surrogate keratin expression. Backed by the Development Bank of Wales with £750K seed funding.